Conventional drug therapies (such as thiopurines and methotrexate) are used in pediatric inflammatory bowel disease (IBD), both as primary maintenance therapy and combined with anti-tumor necrosis factor (TNF) treatment treatment to reduce the risk of developing anti-drug antibodies. Here, TNF is linked to inflammatory bowel disease.